2025 年 05 月 21 日 公司研究 评级：买入(首次覆盖) | 研究所： | | | | --- | --- | --- | | 证券分析师： | | 杨仁文 S0350521120001 | | | | yangrw@ghzq.com.cn | | 证券分析师： | | 谭瑞峤 S0350521120004 | | | | tanrq@ghzq.com.cn | | 联系人 | ： | 王春宸 S0350123070046 | | | | wangcc@ghzq.com.cn | [Table_Title] 经营利润稳健增长，每股分红提升 ——长江传媒（600757）公司动态研究 最近一年走势 | 相对沪深 表现 300 | | | 2025/05/20 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 长江传媒 | 6.1% | 13.2% | 30.7% | | 沪深 300 | 3.3% | -0.8% | 5.6% | | 市场数据 | | | 2025/05/20 | | 当前价格（元） | | | 9.67 | | 周价格区间（元） ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company achieved a revenue of 700 million yuan in Q1 2025, representing a year-on-year increase of 14% and a quarter-on-quarter increase of 3%. However, the net profit attributable to the parent company decreased by 37% year-on-year to 63.49 million yuan, but increased by 81% quarter-on-quarter [6] - In 2024, the company reported a total revenue of 2.6 billion yuan, a year-on-year increase of 44%, with a net profit of 300 million yuan, up 17% year-on-year [6] - The company has seen rapid growth across various downstream sectors, particularly in automotive power management, which grew by 179% year-on-year to 85.51 million yuan [7][8] Financial Performance Summary - The company’s revenue is projected to grow significantly from 2.57 billion yuan in 2024 to 5.34 billion yuan in 2027, with year-on-year growth rates of 44.2%, 31.3%, 25.4%, and 26.4% respectively [11] - The net profit attributable to the parent company is expected to increase from 307 million yuan in 2024 to 704 million yuan in 2027, with corresponding year-on-year growth rates of 17.4%, 26.3%, 29.1%, and 40.6% [11] - The company’s gross margin is projected to remain stable around 40% over the forecast period [11] Investment Recommendations - The forecasted net profits for 2025, 2026, and 2027 are 387 million yuan, 500 million yuan, and 704 million yuan respectively, with corresponding earnings per share (EPS) of 0.91 yuan, 1.18 yuan, and 1.65 yuan. The latest closing price corresponds to price-to-earnings (PE) ratios of 36x, 28x, and 20x for the respective years [9]

证 券 研 究 报 告 山鹰国际（600567）2024 年报及 2025 年一季报点评 推荐（下调） 债务结构持续优化，25Q1 净利率环比转正 目标价：1.96 元 公司研究 事项： 公司公布 2024 年报及 2025 年一季报。2024 年，公司实现营收 292.3 亿元，同 比-0.4%；归母净利润-4.5 亿元，同比由盈转亏；扣非归母净利润-8.4 亿元，亏 损扩大。25Q1，公司实现营收 67.7 亿元，同比+1.5%；归母净利润 0.3 亿元， 同比-16.0%，扣非归母净利润-0.4 亿元，亏损扩大。 评论： 风险提示：原材料价格波动，需求恢复不及预期等 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 29,229 | 29,982 | 31,293 | 32,909 | | 同比增速(%) | -0.4% | 2.6% | 4.4% | 5.2% | | 归母净利润(百万) | -451 | 216 | 339 | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][12]. Core Views - The company's Q1 2025 performance was under pressure due to multiple factors, including high base effects, channel reforms, and centralized procurement, leading to results below market expectations. However, significant improvement is anticipated in Q2 as channel reforms continue and the impact of centralized procurement becomes more favorable [1][8]. - Future outlook includes brand building for Kunzhong Medicine, expected synergy from the acquisition of Huaren Shenghuo, effective channel reforms starting to show results in 2025, and a gradual weakening of external environmental impacts [10][12]. Financial Performance Summary - Q1 2025 financial results showed revenue of 1.608 billion yuan, a year-on-year decline of 16.53%, with net profit at 90 million yuan, down 31.06% [2][8]. - Revenue projections for 2025-2027 are 9.258 billion yuan, 10.244 billion yuan, and 11.350 billion yuan, respectively, with net profits of 725 million yuan, 839 million yuan, and 973 million yuan [3][12]. - Key financial metrics include a projected EPS of 0.96 yuan in 2025, with a P/E ratio decreasing from 26.9 in 2023 to 16.5 in 2025 [3][12]. Segment and Product Line Analysis - The company is focusing on enhancing its "777" brand and expanding its product offerings, particularly in the blood circulation segment, despite facing challenges from centralized procurement and retail integration [9][10]. - The Kunzhong Medicine series is undergoing channel reforms, with expectations for improved sales performance as brand value and channel efficiency are enhanced [9][10]. Strategic Outlook - The company aims to leverage brand culture, product expansion, and IP marketing to strengthen its market position. The integration of the three-seven industry chain with Huaren Shenghuo is expected to enhance market competitiveness [10][12]. - The anticipated results of channel reforms are expected to manifest in 2025, with a forecast of double-digit revenue growth and matching net profit growth [10][12].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% [4][23]. Core Views - The company has shown stable revenue growth despite external industry challenges, with Q1 2025 revenue at 2.055 billion yuan, a year-on-year increase of 0.30%. The net profit attributable to shareholders was 314 million yuan, up 6.47% year-on-year, while the net profit after deducting non-recurring items decreased by 19.54% [2][8]. - The company is focusing on enhancing R&D capabilities and modernizing traditional Chinese medicine, with expectations for stable growth in the traditional Chinese medicine sector and new product introductions in chemical and biological pharmaceuticals [1][10][11]. - The strategic integration with China Resources is progressing well, which is anticipated to strengthen the company's competitive position in the market [12]. Financial Performance Summary - For Q1 2025, the company achieved a revenue of 2.055 billion yuan, with a net profit of 314 million yuan. The core pharmaceutical segment generated 1.842 billion yuan in revenue, reflecting a 1.83% increase year-on-year [2][9]. - The company’s gross margin for Q1 2025 was 66.61%, a slight decrease of 0.55 percentage points year-on-year, indicating stable profitability despite pricing pressures [13]. - The forecast for revenue from 2025 to 2027 is projected to be 9.001 billion yuan, 9.539 billion yuan, and 10.129 billion yuan, respectively, with corresponding net profits of 1.074 billion yuan, 1.216 billion yuan, and 1.386 billion yuan, reflecting growth rates of 12.4%, 13.3%, and 14.0% [16].

公司研究 证 券 研 究 报 告 可靠股份（301009）2024 年报及 2025 年一季报点评 推荐（维持） 成本结构持续优化，自有品牌加速培育 目标价：16.1 元 华创证券研究所 证券分析师：刘一怡 邮箱：liuyiyi@hcyjs.com 执业编号：S0360524070003 事项： 公司公布 2024 年年报及 2025 年一季报。2024 年，公司实现营收/归母净利润 /扣非归母净利润 10.8/0.3/0.2 亿元，同比-0.3%/+54.4%/+33.1%。25Q1，公司实 现营收/归母净利润/扣非归母净利润 2.8/0.2/0.2 亿元，同比-1.0%/+1.4%/-3.5%。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,079 | 1,152 | 1,256 | 1,393 | | 同比增速(%) | -0.3% | 6.8% | 9.0% | 10.9% | | 归母净利润(百万) | 31 | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][12]. Core Insights - The company has shown steady growth in its core business, with profit growth exceeding expectations due to a strong industrial segment and effective cost control [1][8][10]. - For Q1 2025, the company achieved total revenue of 10.841 billion yuan, a year-on-year increase of 0.62%, and a net profit attributable to shareholders of 1.935 billion yuan, up 13.67% year-on-year [2][8]. Financial Performance - Key financial indicators for the company are as follows: - Revenue (million yuan): 39,111 in 2023, projected to reach 41,691 in 2025E, with a CAGR of 4.1% [3]. - Net profit (million yuan): 4,094 in 2023, projected to reach 5,124 in 2025E, with a CAGR of 7.9% [3]. - Gross margin: Expected to increase from 26.5% in 2023 to 28.5% in 2025E [3]. - Net margin: Expected to rise from 10.5% in 2023 to 12.3% in 2025E [3]. - ROE: Expected to improve from 10.3% in 2023 to 12.8% in 2025E [3]. - EPS: Projected to grow from 2.29 yuan in 2023 to 2.87 yuan in 2025E [3]. Business Segments - The company is focusing on enhancing its core product lines, particularly in the pharmaceutical division, which is expected to achieve steady growth driven by its flagship products [9][10]. - The health products division is anticipated to maintain stable operations despite industry pressures, with innovations in oral care and hair care products [9][10]. - The traditional Chinese medicine resources division is expected to grow due to ongoing brand development and market leadership in specific herbal products [9][10]. Future Outlook - The company aims to solidify its main business while exploring new growth opportunities in emerging sectors such as health supplements and medical devices [10][12]. - Revenue projections for 2025-2027 are 41.691 billion yuan, 43.593 billion yuan, and 45.734 billion yuan, respectively, with net profit forecasts of 5.124 billion yuan, 5.622 billion yuan, and 6.203 billion yuan [12].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [9]. Core Insights - The company is positioned to benefit from the ongoing transformation in the ASIC chip sector, leveraging its IP resources and R&D capabilities to provide comprehensive chip customization services. The new orders for mass production are expected to grow by 180% in 2024 compared to 2023, driven by the surge in demand from AI and IoT [9]. - The recent launch of NVIDIA's NVLink Fusion is expected to lower the barriers for third-party development of high-performance interconnect chips, which will accelerate the deployment of dedicated processing chips in the internet sector, further benefiting the company [9]. - The company's stock is currently trading at a price-to-sales (PS) ratio of 9 times for 2027, maintaining the "Buy" recommendation [9]. Financial Summary - The company reported a revenue of RMB 3.9 billion in Q1 2025, reflecting a year-over-year growth of 22.5%. However, it incurred a loss of RMB 2.2 billion, which is an increase in losses compared to the previous year [13]. - The projected revenues for 2025, 2026, and 2027 are RMB 30.7 billion, RMB 38.4 billion, and RMB 47.4 billion, respectively, with year-over-year growth rates of 32%, 25%, and 23% [13]. - The net profit forecast for 2025 is a loss of RMB 0.26 billion, followed by a profit of RMB 0.53 billion in 2026 and RMB 2 billion in 2027, with corresponding earnings per share (EPS) of -0.05, 0.11, and 0.40 [13].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported strong performance with record highs in its two main business segments [1] - In 2024, the company achieved operating revenue of 15.374 billion, a year-on-year increase of 21.15%, and a net profit attributable to shareholders of 917 million, up 86.62% year-on-year, primarily due to market expansion [4][5] - The company has increased its R&D expenditure to 575 million, a growth of 17.42%, leading to multiple breakthroughs in technology [4] - The company is capitalizing on policy opportunities, with domestic and international businesses flourishing, particularly in the electric vehicle charging sector, which has seen a 131.87% increase in overseas contracts [5] Financial Summary - The company’s projected net profits for 2025, 2026, and 2027 are adjusted to 1.2 billion, 1.5 billion, and 2.1 billion respectively, with corresponding P/E ratios of 20, 16, and 12 [6] - Key financial metrics for 2024 include a gross margin of 25.9%, a return on equity (ROE) of 12.3%, and earnings per share (EPS) of 0.89 [8] - The company’s operating revenue is expected to grow to 19.092 billion in 2025, reflecting a year-on-year growth of 24.2% [8]

公司近一年市场表现 | 市场数据：2025 年 | 月 5 | 日 20 | | | --- | --- | --- | --- | | 收盘价（元）： | | | 21.27 | | 总股本（亿股）： | | | 6.28 | | 流通股本（亿股）： | | | 6.28 | | 流通市值（亿元）： | | | 133.57 | | 基础数据：2025 年 3 月 | 31 日 | | --- | --- | | 每股净资产（元）： | 3.86 | | 每股资本公积（元）： | 2.06 | | 每股未分配利润（元）： | 0.56 | | 资料来源：最闻 | | 高宇洋 执业登记编码：S0760523050002 执业登记编码：S0760523120001 邮箱：zhangtian@sxzq.com 赵天宇 执业登记编码：S0760524060001 邮箱：zhaotianyu@sxzq.com 其他军工Ⅲ 上海瀚讯（300762.SZ） 买入-B(维持) 2024 卫星业务收入超 1.5 亿，2025 G60 星链发射数量大幅增 事件描述： 2025 年 5 月 21 日 公司研究/公司快报 上海瀚讯 ...